Brontictuzumab, CAS 1447814-75-6

Product Description: Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma[1][2][3].

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]Ferrarotto R, et al. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018 Jul 1;29(7):1561-1568. /[2]Silkenstedt E, et al. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. J Exp Clin Cancer Res. 2019 Nov 1;38(1):446. /[3]Agnusdei V, et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia. 2014 Feb;28(2):278-88.

CAS Number: 1447814-75-6

Molecular Weight: N/A

Compound Purity: 95.00

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Notch

• Artikelnummer: MEXHY-P99258-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99258-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK